Akèy › Lymphome de Hodgkin › Texas
Etid klinik pou Lymphome de Hodgkin nan Texas
15 etid pou Lymphome de Hodgkin ap chèche patisipan nan sit nan Texas.
Vil nan Texas
Tèks ofisyèl etid la (Anglè)
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
Ap rekriteFaz 1
Laj 12 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT06176690CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
Ap rekriteFaz 1
Laj 12 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT02917083Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Texas Children's Hospital, Houston
Ap rekriteEtid obsèvasyon
Laj 0 a 38 · Tout sèks · Mizajou Oct 1, 2026 · NCT06131801A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
- M D Anderson Cancer Center, Houston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT05615636Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
- Sarah Cannon Research Institute at St. David's South Austin, Austin
Ap rekriteFaz 1
Laj 18 a 100 · Tout sèks · Mizajou Sep 15, 2026 · NCT05798897AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
- Research Site, Houston
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT06137144Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies
- The University of Texas M. D. Anderson Cancer Center, Houston
Ap rekriteFaz 1
Laj 18 a 75 · Tout sèks · Mizajou Sep 8, 2026 · NCT07444632Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL
- UT MD Anderson, Houston
Ap rekriteFaz 2
Laj 2 a 21 · Tout sèks · Mizajou Aug 31, 2026 · NCT07551583Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
- M D Anderson Cancer Center, Houston
Ap rekriteFaz 1/2
Laj 12 a 80 · Tout sèks · Mizajou Aug 7, 2026 · NCT05092451Personalized NK Cell Therapy in CBT
- M D Anderson Cancer Center, Houston
Ap rekriteFaz 2
Laj 15 a 80 · Tout sèks · Mizajou Jul 30, 2026 · NCT02727803A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Medical City Dallas, Dallas
- Children's Medical Center Dallas, Dallas
- Zachary & Elizabeth Fisher Bone Marrow Transplant Program (Brooke Army Medical Center), Fort Sam Houston
- ak 5 plis
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Jul 6, 2026 · NCT01351545EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma
- Harris Health System - Ben Taub General Hospital/Smith Clinic, Houston
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
- ak 1 plis
Ap rekriteFaz 1
Tout laj · Tout sèks · Mizajou Jun 25, 2026 · NCT04664179A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma
- MD Anderson Cancer Center, Houston
Ap rekriteFaz 2Volontè an sante akeyi
Laj 1 ak plis · Tout sèks · Mizajou May 18, 2026 · NCT05355051Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- Harris Health System (includes ben Taub General Hospital and Smith), Houston
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
Ap rekriteFaz 1
Tout laj · Tout sèks · Mizajou Mar 2, 2026 · NCT01555892Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- University of Texas, Southwestern, Dallas
- Cook Children's Hospital, Fort Worth
- Texas Children's Hospital/Baylor College of Medicine, Houston
Ap rekriteFaz 1
Laj 1 a 21 · Tout sèks · Mizajou Dec 6, 2024 · NCT05476770Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.